LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
Search Results
Nikkei Japan Reports the Status of MEDIPOST’s Stem Cell Research
2015/01/07
43% Increase in Dosage of CARTISTEM, for 4th Quarter of 2014 Year on Year
2014/12/30
MEDIPOST will set up a joint venture company in China
2014/12/10
Korean stem cells regenerate coach Hiddink’s worn-out knee cartilage
2014/11/06
Lung disease stem cell treatment drug ‘PNEUMOSTEM’ application for US clinical t…
2014/08/12
Lung disease stem cell drug designated ‘orphan drug in development stage’
2014/07/29
Hiddink, designated MEDIPOST Cord Blood Honorary Ambassador
2014/07/23
Stem Cell Drug ‘CARTISTEM’ Treatment Japanese Patent
2014/07/10
US patent for ‘CARTISTEM’ raw material stem cell differentiation capability sele…
2014/05/15
Successful administration of stem cell dementia treatment drug ‘NEUROSTEM’
2014/04/28
Japan patent for dementia treatment technology using stem cell
2014/04/17
Stem cell treatment ‘CARTISTEM’ patient cutting the 10 million line
2014/03/27
Previous
1
…
9
10
11
12
13
14
Next
Menu